LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

近患者丙肝测定得到确证

By LabMedica International staff writers
Posted on 03 Jun 2018
Print article
图片:Genedrive HCV ID试剂盒是一种定性测定,在去中心化的环境下运行,90分钟出结果(图片蒙Genedrive公司惠赐)。
图片:Genedrive HCV ID试剂盒是一种定性测定,在去中心化的环境下运行,90分钟出结果(图片蒙Genedrive公司惠赐)。
丙肝病毒(HCV)的慢性感染是一种主要的公共卫生问题,据估计感染了世界1.0%的人口(7100万人),肝硬化和肝癌每年致死40万人。
 
一种手持式便携设备仅重600克左右,略大于21盎司,经过确证,可作为丙肝病毒的床旁分子诊断系统与测定产品。一项新研究用熔峰比率分析验证了对HCV病毒载量进行半定量评估这一概念。
 
来自多国的一组科学家与法国巴黎巴斯德研究所(www.pasteur.fr)的科学家合作,让四名操作员用三台仪器检验了130份临床血浆样本与血清样本。从多个非洲国家收集样本,包括加纳、肯尼亚、毛里求斯、莫桑比克、尼日利亚、南非、乌干达和津巴布韦,在雅培实验室(Abbott Park, IL, USA; www.molecular.abbott)的m2000上使用RealTime HCV Genotype II检验,这属于HCV常规诊断检验的一部分。
 
科研小组确证了英国曼彻斯特Genedrive公司(www.genedriveplc.com)的床旁(POC) HCV测定,检验过程分两步,先制备血浆或血清,再进行逆转录(RT)反应,用目标HCV RNA生成互补DNA (cDNA)。cDNA经过非对称聚合酶链反应(PCR),生成单链产品的线性扩增,然后用一只次级杂交探针检测,再做解离曲线分析。
 
这款床旁测定产品识别出全部的HCV基因型,检测限为2,362 IU/毫升(95%置信区间为1966 - 2788)。选取422名HCV慢性感染患者与503名抗HCV抗体和HCV RNA阴性的对照者,Genedrive HCV测定的灵敏度为98.6%(95%置信区间为96.9% - 99.5%),特异性为100%(95%置信区间为99.3% - 100%)。此外,熔峰比率分析验证了HCV半定量评估的原理。在一个资源有限的国家的真实临床场合进一步确证了这项检验。
 
该研究的论文发表于2018年4月3日的《BMJ Gut》杂志。作者总结说,他们在真实临床场合证明了一个概念——Genedrive HCV测定非常有望为分布式HCV核酸扩增检验(NAAT)提供一台价格适中、性能可靠的仪器。这种高度灵敏特异的检验最近获得了CE-IVD认证,将能够在任何临床场合实时管理丙肝慢性感染患者的治疗。
 
Related Links:

巴斯德研究所>>> www.pasteur.fr

雅培实验室>>> www.molecular.abbott

Genedrive >>> www.genedriveplc.com


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more